Skip to main content
Top
Gepubliceerd in: Quality of Life Research 3/2017

06-01-2017

Quality of life with rivaroxaban in patients with non-valvular atrial fibrilation by therapeutic compliance

Auteurs: Emilio Márquez-Contreras, Nieves Martell-Claros, Vicente Gil-Guillén, Mariano De la Figuera-Von Wichmann, Eugenio Sánchez-López, Ines Gil-Gil, Sara Márquez-Rivero, Working Group on Compliance and Inertia. Spanish Society of Hypertension

Gepubliceerd in: Quality of Life Research | Uitgave 3/2017

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Objective

To assess the quality of life (QOL) with rivaroxaban in patients with non-valvular atrial fibrilation (NVAF) related to therapeutic compliance.

Methods

Prospective, longitudinal, multicenter study was developed in 160 Spanish primary or specialized care centers. We included 412 patients treated with rivaroxaban, prescribed for stroke prevention. Three visits were conducted: baseline, 6 and 12 months. Compliance was measured by electronic monitoring systems. QOL was measured by a specific questionnaire. We calculated the percentage of compliance means, the percentage of daily compliers and the score of QOL.

Results

Three hundred and seventy patients finished the study (mean age 75.19 SD: 7.5 years). Daily compliance was 83.5% (CI 78.53–88.57%) (n = 309) and 80% (CI 74.65–85.35%) at 6 and 12 months, respectively. Average QOL rating was 112.85 (SD 29.31) in non-compliant and 111.80 (SD 29.31) in the compliant group (p = Not significant), and after 12 months of 124.67 (SD 30.78) and 83.47 (SD 26.44), respectively (p < 0.0001), with a decrease in the score compliers (p < 0.01) and an increase in non-compliant group (p < 0.05). A higher number of drugs consumed, as well as the number of diseases/conditions suffered, the older age of the patients and having been previously treated with VKA were associated with a higher overall score (worse QOL).

Conclusions

QOL in NVAF patients treated with rivaroxaban improved significantly over the study group at the expense of compliers. A worse QOL was associated with pluripathology, polymedication, older patients and previous treatment with VKA.
Literatuur
1.
go back to reference Mani, H., & Lindhoff-Last, E. (2014). New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness. Drug Design Development and Therapy, 8, 789–798.CrossRef Mani, H., & Lindhoff-Last, E. (2014). New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness. Drug Design Development and Therapy, 8, 789–798.CrossRef
2.
go back to reference Potpara, T. S., Jokic, V., Medic, B., Prostran, M., & Lip, G. Y. (2015). An update on atrial fibrillation: focus on stroke risk reduction strategies. Minerva Medica, 106, 259–273.PubMed Potpara, T. S., Jokic, V., Medic, B., Prostran, M., & Lip, G. Y. (2015). An update on atrial fibrillation: focus on stroke risk reduction strategies. Minerva Medica, 106, 259–273.PubMed
3.
go back to reference Hernández Olmedo, M., & Suárez, Fernández C. (2015). Progress of anticoagulation therapy in atrial fibrillation. Medicina Clinica (BARC), 145, 124–130.CrossRef Hernández Olmedo, M., & Suárez, Fernández C. (2015). Progress of anticoagulation therapy in atrial fibrillation. Medicina Clinica (BARC), 145, 124–130.CrossRef
4.
go back to reference de Andrés-Nogales, F., Oyagüez, I., Betegón-Nicolás, L., Canal-Fontcuberta, C., & Soto-Álvarez, J. (2015). Status of oral anticoagulant treatment in patients with nonvalvular atrial fibrillation in Spain. REACT-AF Study. Rev Clin Esp, 215, 73–82.CrossRefPubMed de Andrés-Nogales, F., Oyagüez, I., Betegón-Nicolás, L., Canal-Fontcuberta, C., & Soto-Álvarez, J. (2015). Status of oral anticoagulant treatment in patients with nonvalvular atrial fibrillation in Spain. REACT-AF Study. Rev Clin Esp, 215, 73–82.CrossRefPubMed
5.
go back to reference Camm, A. J., Lip, G. Y., de Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., et al (2012). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace, 14, 1385–413.CrossRef Camm, A. J., Lip, G. Y., de Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., et al (2012). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace, 14, 1385–413.CrossRef
6.
go back to reference Hernández Olmedo, M., & Suárez, Fernández C. (2015). Progress of anticoagulation therapy in atrial fibrillation. Medicina Clinica (BARC), 145, 124–130.CrossRef Hernández Olmedo, M., & Suárez, Fernández C. (2015). Progress of anticoagulation therapy in atrial fibrillation. Medicina Clinica (BARC), 145, 124–130.CrossRef
7.
go back to reference Miller, C. S., Grandi, S. M., Shimony, A., Filion, K. B., & Eisenberg, M. J. (2012). Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. The American Journal of Cardiology, 110, 453–460.CrossRefPubMed Miller, C. S., Grandi, S. M., Shimony, A., Filion, K. B., & Eisenberg, M. J. (2012). Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. The American Journal of Cardiology, 110, 453–460.CrossRefPubMed
8.
go back to reference Newby, L. K., LaPointe, N. M., Chen, A. Y., Kramer, J. M., Hammill, B. G., DeLong, E. R., et al. (2006). Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation, 113, 203–212.CrossRefPubMed Newby, L. K., LaPointe, N. M., Chen, A. Y., Kramer, J. M., Hammill, B. G., DeLong, E. R., et al. (2006). Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation, 113, 203–212.CrossRefPubMed
9.
go back to reference Amin, A., & Marrs, J. C. (2016). Direct oral anticoagulants for the management of thromboembolic disorders: The importance of adherence and persistence in achieving beneficial outcomes. Clin Appl Thromb Hemost, 22, 605–616.CrossRefPubMed Amin, A., & Marrs, J. C. (2016). Direct oral anticoagulants for the management of thromboembolic disorders: The importance of adherence and persistence in achieving beneficial outcomes. Clin Appl Thromb Hemost, 22, 605–616.CrossRefPubMed
10.
go back to reference Martinez, C., Katholing, A., Wallenhorst, C., & Freedman, S. B. (2016). Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemost, 115, 31–39.CrossRefPubMed Martinez, C., Katholing, A., Wallenhorst, C., & Freedman, S. B. (2016). Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemost, 115, 31–39.CrossRefPubMed
11.
go back to reference Gusmai Lde, F., Novato Tde, S., & Nogueira, Lde S. (2015). The influence of quality of life in treatment adherence of diabetic patients: a systematic review. Revista da Escola Enfermagem da USP, 49, 839–846.CrossRef Gusmai Lde, F., Novato Tde, S., & Nogueira, Lde S. (2015). The influence of quality of life in treatment adherence of diabetic patients: a systematic review. Revista da Escola Enfermagem da USP, 49, 839–846.CrossRef
12.
go back to reference Miller, C. S., Grandi, S. M., Shimony, A., Filion, K. B., & Eisenberg, M. J. (2012). Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. The American Journal of Cardiology, 110, 453–460.CrossRefPubMed Miller, C. S., Grandi, S. M., Shimony, A., Filion, K. B., & Eisenberg, M. J. (2012). Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. The American Journal of Cardiology, 110, 453–460.CrossRefPubMed
13.
go back to reference Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., et al. (2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine, 365, 883–891.CrossRefPubMed Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., et al. (2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine, 365, 883–891.CrossRefPubMed
14.
go back to reference Camm, A. J., Amarenco, P., Haas, S., Hess, S., Kirchhof, P., Kuhls, S., et al. (2016). XANTUS: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Europe Heart Journal, 37, 1145–1153.CrossRef Camm, A. J., Amarenco, P., Haas, S., Hess, S., Kirchhof, P., Kuhls, S., et al. (2016). XANTUS: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Europe Heart Journal, 37, 1145–1153.CrossRef
15.
go back to reference Fox, K. A. A., Piccini, J. P., Wojdyla, D., Becker, R. C., Halperin, J. L., Nessel, C. C., et al. (2011). Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Europe Heart Journal, 32, 2387–2394.CrossRef Fox, K. A. A., Piccini, J. P., Wojdyla, D., Becker, R. C., Halperin, J. L., Nessel, C. C., et al. (2011). Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Europe Heart Journal, 32, 2387–2394.CrossRef
16.
go back to reference Sawicki, P. T. (1999). A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. Working group for the Study of Patient Self-Management of Oral Anticoagulation. JAMA, 281, 145–150.CrossRefPubMed Sawicki, P. T. (1999). A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. Working group for the Study of Patient Self-Management of Oral Anticoagulation. JAMA, 281, 145–150.CrossRefPubMed
17.
go back to reference Sánchez González, R., Yanes Baonza, M., Cabrera Majada, A., Ferrer García-Borrás, J. M., Alvarez Nido, R., & Barrera, Linares E. (2004). Adaptación transcultural de un cuestionario para medir la calidad de vida de los pacientes con anticoagulación oral. Atención Primaria, 34, 353–359.CrossRefPubMed Sánchez González, R., Yanes Baonza, M., Cabrera Majada, A., Ferrer García-Borrás, J. M., Alvarez Nido, R., & Barrera, Linares E. (2004). Adaptación transcultural de un cuestionario para medir la calidad de vida de los pacientes con anticoagulación oral. Atención Primaria, 34, 353–359.CrossRefPubMed
18.
go back to reference Gadisseur, A. P., Kaptein, A. A., Breukink-Engbers, W. G., de Mol, B. J., Prins, M. H., Hutten, B. A., et al. (2004). Patient self-management of oral anticoagulant care vs. management by specialized anticoagulation clinics: Positive effects on quality of life. Journal of Thrombosis and Haemostasis, 2, 584–591.CrossRefPubMed Gadisseur, A. P., Kaptein, A. A., Breukink-Engbers, W. G., de Mol, B. J., Prins, M. H., Hutten, B. A., et al. (2004). Patient self-management of oral anticoagulant care vs. management by specialized anticoagulation clinics: Positive effects on quality of life. Journal of Thrombosis and Haemostasis, 2, 584–591.CrossRefPubMed
19.
go back to reference Siebenhofer, A., Hemkens, L. G., Rakovac, I., Spat, S., & Didjurgeit, U. (2012). Self-management of oral anticoagulation in elderly patients—effects on treatment-related quality of life. Thromb Res, 130, e60–e66.CrossRefPubMed Siebenhofer, A., Hemkens, L. G., Rakovac, I., Spat, S., & Didjurgeit, U. (2012). Self-management of oral anticoagulation in elderly patients—effects on treatment-related quality of life. Thromb Res, 130, e60–e66.CrossRefPubMed
20.
go back to reference Alegret, J. M., Viñolas, X., Arias, M. A., Martínez-Rubio, A., Rebollo, P., Ràfols, C., et al. (2014). New oral anticoagulants vs vitamin K antagonists: benefits for health-related quality of life in patients with atrial fibrillation. International Journal Medical Sciences, 11, 680–684.CrossRef Alegret, J. M., Viñolas, X., Arias, M. A., Martínez-Rubio, A., Rebollo, P., Ràfols, C., et al. (2014). New oral anticoagulants vs vitamin K antagonists: benefits for health-related quality of life in patients with atrial fibrillation. International Journal Medical Sciences, 11, 680–684.CrossRef
21.
go back to reference Yanes Baonza, M., Cabrera Majada, A., Ferrer García-Borrás, J. M., & Sánchez, González R. (2005). Quality of life of patients treated with oral anticoagulants. Atencion Primaria, 36, 224–225.CrossRefPubMed Yanes Baonza, M., Cabrera Majada, A., Ferrer García-Borrás, J. M., & Sánchez, González R. (2005). Quality of life of patients treated with oral anticoagulants. Atencion Primaria, 36, 224–225.CrossRefPubMed
22.
go back to reference De Schryver, E. L., van Gijn, J., Kappelle, L. J., Koudstaal, P. J., Algra, A., Dutch, T. I. A., et al. (2005). Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischaemic stroke. Journal of Neurology, 252, 1316–1321.CrossRefPubMed De Schryver, E. L., van Gijn, J., Kappelle, L. J., Koudstaal, P. J., Algra, A., Dutch, T. I. A., et al. (2005). Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischaemic stroke. Journal of Neurology, 252, 1316–1321.CrossRefPubMed
23.
go back to reference Nelson, W. W., Song, X., Thomson, E., Smith, D. M., Coleman, C. I., Damaraju, C. V., et al. (2015). Medication persistence and discontinuation of rivaroxaban and dabigatran etexilate among patients with non-valvular atrial fibrilation. Current Medical Resarch and Opinion, 31, 1831–1840.CrossRef Nelson, W. W., Song, X., Thomson, E., Smith, D. M., Coleman, C. I., Damaraju, C. V., et al. (2015). Medication persistence and discontinuation of rivaroxaban and dabigatran etexilate among patients with non-valvular atrial fibrilation. Current Medical Resarch and Opinion, 31, 1831–1840.CrossRef
24.
go back to reference Crivera, C., Nelson, W. W., Bookhart, B., Martin, S., Germain, G., Laliberté, F., et al. (2015). Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications. Current Medicine Resarch and Opinion, 31, 1889–1895.CrossRef Crivera, C., Nelson, W. W., Bookhart, B., Martin, S., Germain, G., Laliberté, F., et al. (2015). Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications. Current Medicine Resarch and Opinion, 31, 1889–1895.CrossRef
25.
go back to reference Ynsaurriaga, F. A., Peinado, R. P., & Ormaetxe Merodio, J. M. (2014). Atrial fibrillation and quality of life related to disease and treatment: focus on anticoagulation. Future Cardiology, 10, 381–393.CrossRefPubMed Ynsaurriaga, F. A., Peinado, R. P., & Ormaetxe Merodio, J. M. (2014). Atrial fibrillation and quality of life related to disease and treatment: focus on anticoagulation. Future Cardiology, 10, 381–393.CrossRefPubMed
26.
go back to reference Cromheecke, M. E., Levi, M., Colly, L. P., De Mol, B. J. M., Prins, M. H., Hutten, B. A., et al. (2000). Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. The Lancet, 356, 97–102.CrossRef Cromheecke, M. E., Levi, M., Colly, L. P., De Mol, B. J. M., Prins, M. H., Hutten, B. A., et al. (2000). Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. The Lancet, 356, 97–102.CrossRef
27.
go back to reference Sawicki, P. T., Gläser, B., Kleespies, C., Stubbe, J., Schmitz, N., Kaiser, T., et al. (2003). Self-management of oral anticoagulation: long-term results. Journal of Internal Medicine, 254, 515–516.CrossRefPubMed Sawicki, P. T., Gläser, B., Kleespies, C., Stubbe, J., Schmitz, N., Kaiser, T., et al. (2003). Self-management of oral anticoagulation: long-term results. Journal of Internal Medicine, 254, 515–516.CrossRefPubMed
28.
go back to reference Hasan, S. S., Teh, K. M., Ahmed, S. I., Chong, D. W., Ong, H. C., & Naina, B. (2015). Quality of life (QoL) and international normalized ratio (INR) control of patients attending anticoagulation clinics. Public Health, 129, 954–962.CrossRefPubMed Hasan, S. S., Teh, K. M., Ahmed, S. I., Chong, D. W., Ong, H. C., & Naina, B. (2015). Quality of life (QoL) and international normalized ratio (INR) control of patients attending anticoagulation clinics. Public Health, 129, 954–962.CrossRefPubMed
29.
go back to reference Fareau, S., Baumstarck, K., Farcet, A., Molines, C., Auquier, P., & Retornaz, F. (2015). Quality of life of elderly people on oral anticoagulant for atrial fibrillation: VKA versus direct oral anticoagulants. Geriatrie et Psychologie Neuropsychiatrie du Vieillissement, 13, 45–54.PubMed Fareau, S., Baumstarck, K., Farcet, A., Molines, C., Auquier, P., & Retornaz, F. (2015). Quality of life of elderly people on oral anticoagulant for atrial fibrillation: VKA versus direct oral anticoagulants. Geriatrie et Psychologie Neuropsychiatrie du Vieillissement, 13, 45–54.PubMed
30.
go back to reference Freeman, J. V., Simon, D. N., Go, A. S., Spertus, J., Fonarow, G. C., Gersh, B. J., et al. (2015). Association between atrial fibrillation symptoms, quality of life, and patient outcomes: results from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF). Circulation Cardiovascular Quality and Outcomes, 8, 393–402.CrossRefPubMed Freeman, J. V., Simon, D. N., Go, A. S., Spertus, J., Fonarow, G. C., Gersh, B. J., et al. (2015). Association between atrial fibrillation symptoms, quality of life, and patient outcomes: results from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF). Circulation Cardiovascular Quality and Outcomes, 8, 393–402.CrossRefPubMed
31.
go back to reference de Almeida, G., Noblat Lde, A., Passos, L. C., & do Nascimento, H. F. (2011). Quality of life analysis of patients in chronic use of oral anticoagulant: an observational study. Health Quality Life Outcomes, 9, 91.CrossRef de Almeida, G., Noblat Lde, A., Passos, L. C., & do Nascimento, H. F. (2011). Quality of life analysis of patients in chronic use of oral anticoagulant: an observational study. Health Quality Life Outcomes, 9, 91.CrossRef
Metagegevens
Titel
Quality of life with rivaroxaban in patients with non-valvular atrial fibrilation by therapeutic compliance
Auteurs
Emilio Márquez-Contreras
Nieves Martell-Claros
Vicente Gil-Guillén
Mariano De la Figuera-Von Wichmann
Eugenio Sánchez-López
Ines Gil-Gil
Sara Márquez-Rivero
Working Group on Compliance and Inertia. Spanish Society of Hypertension
Publicatiedatum
06-01-2017
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 3/2017
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-016-1489-x

Andere artikelen Uitgave 3/2017

Quality of Life Research 3/2017 Naar de uitgave